How India Exports Ibuprofen to the World

In the United States, ibuprofen is available both over-the-counter (OTC) and by prescription, depending on the dosage and formulation. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for ibuprofen, indicating a competitive generic market. Indian exporters must ensure compliance with FDA regulations, including facility registration and product listing, to access the U.S. market. Importers are required to file an entry notice and bond with U.S. Customs, pending FDA's admissibility decision. The FDA employs Import Alerts to detain products with known violations without physical examination. As of March 2026, there are no specific Import Alerts related to ibuprofen from India, but exporters should remain vigilant to maintain compliance.

In the European Union, ibuprofen is subject to marketing authorization by the European Medicines Agency (EMA) or national competent authorities. For instance, in February 2024, the EMA recommended refusing authorization for Ibuprofen NVT 400 mg soft capsules due to concerns over bioequivalence. Conversely, in July 2020, the EMA recommended authorizing Ibuprofen Kabi 400 mg solution for infusion, recognizing its benefits over risks. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees ibuprofen's regulation. In February 2026, the MHRA issued a Class 3 Medicines Recall for specific batches of ibuprofen 200 mg tablets due to packaging defects. (ema.europa.eu)

Ibuprofen is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in basic healthcare systems. It is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, ibuprofen is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international standards and regulations.

The primary patents for ibuprofen have expired, leading to a robust generic market with significant competition among manufacturers. This competitive landscape has contributed to the widespread availability and affordability of ibuprofen globally.

In February 2024, the EMA recommended refusing authorization for Ibuprofen NVT 400 mg soft capsules due to bioequivalence concerns. (ema.europa.eu) In February 2026, the MHRA issued a Class 3 Medicines Recall for specific batches of ibuprofen 200 mg tablets due to packaging defects. (gov.uk) In November 2023, the EMA conducted a Periodic Safety Update Report (PSUR) single assessment for ibuprofen, leading to variations in product information to enhance safety measures. (ema.europa.eu)

These developments highlight the dynamic regulatory environment surrounding ibuprofen, emphasizing the need for exporters to stay informed and compliant with international standards.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of KSMs are imported from China, creating a significant dependency. This reliance poses risks, as disruptions in Chinese supply chains can lead to shortages and increased costs for Indian manufacturers. For instance, during the COVID-19 pandemic, lockdowns and export restrictions in China caused delays in KSM shipments, impacting API production timelines.

To mitigate this dependency, the Indian government launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in 2020, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, the scheme has led to the establishment of manufacturing capacity for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore, including exports of ₹508 crore, thereby avoiding imports worth ₹1,807 crore.

The ibuprofen export market from India exhibits a high supplier concentration, with the top five exporters accounting for 59.5% of total exports. Mylan Laboratories Limited leads with a 22.8% share, followed by Granules India Limited (10.8%), Caplin Point Laboratories Limited (9.3%), Marksans Pharma Limited (9.2%), and Strides Pharma Science Limited (7.4%). This concentration poses a single-source risk, as disruptions affecting these key suppliers could significantly impact global ibuprofen availability.

The PLI Scheme for Bulk Drugs, initiated in 2020, aims to reduce such risks by encouraging diversification and enhancing domestic production capabilities. By September 2025, the scheme had attracted investments exceeding initial commitments, with ₹4,763.34 crore invested over three and a half years, surpassing the committed ₹4,329.95 crore over six years. This initiative is expected to bolster the resilience of the pharmaceutical supply chain by reducing reliance on a limited number of suppliers.

Geopolitical tensions and shipping disruptions pose significant risks to the pharmaceutical supply chain. The Red Sea and the Strait of Hormuz are critical maritime routes for global trade, including pharmaceutical shipments. Any instability in these regions, such as conflicts or blockades, can delay shipments and increase transportation costs. Additionally, escalating tensions between the United States and China have led to trade restrictions and tariffs, potentially affecting the availability and cost of KSMs imported from China.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various drugs due to supply chain disruptions. For example, in February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP), highlighting ongoing quality concerns and the impact of regulatory actions on supply chains.

• Diversify Supplier Base: Encourage the development of alternative suppliers for KSMs and APIs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Continue to support and expand initiatives like the PLI Scheme to boost domestic manufacturing of critical pharmaceutical components.

• Strengthen Quality Control: Implement stringent quality assurance measures to ensure compliance with international standards, reducing the risk of regulatory actions that can disrupt supply chains.

• Develop Strategic Reserves: Establish reserves of essential KSMs and APIs to buffer against short-term supply disruptions.

• Monitor Geopolitical Developments: Stay informed about international political and trade developments to anticipate and mitigate potential impacts on the supply chain.

RISK_LEVEL: MEDIUM